贝达药业
(300558)
| 流通市值：150.42亿 | | | 总市值：150.82亿 |
| 流通股本：4.17亿 | | | 总股本：4.18亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 735,775,468.8 | 2,456,196,486.62 | 2,043,551,452.9 | 1,313,877,968.81 |
| 营业收入 | 735,775,468.8 | 2,456,196,486.62 | 2,043,551,452.9 | 1,313,877,968.81 |
| 二、营业总成本 | 641,561,760.14 | 2,213,916,621.77 | 1,805,104,808.62 | 1,230,251,651.55 |
| 营业成本 | 128,543,650.38 | 404,482,752.66 | 293,316,382.2 | 207,618,286.83 |
| 税金及附加 | 5,111,271.91 | 14,066,610.05 | 13,808,023.85 | 9,111,101.5 |
| 销售费用 | 230,482,714.67 | 853,886,240.4 | 709,516,053.44 | 457,912,599.45 |
| 管理费用 | 114,726,159.34 | 261,755,974.75 | 292,166,382.44 | 203,647,757.58 |
| 研发费用 | 152,750,433.4 | 640,138,657.34 | 467,939,305.01 | 334,517,734.07 |
| 财务费用 | 9,947,530.44 | 39,586,386.57 | 28,358,661.68 | 17,444,172.12 |
| 其中:利息费用 | 11,007,909.82 | 54,954,618.01 | 42,186,589.71 | 30,003,997.82 |
| 其中:利息收入 | 2,640,174.93 | 10,234,964.82 | 7,333,925.93 | 5,029,779.12 |
| 加:公允价值变动收益 | - | -312,610.4 | - | - |
| 加:投资收益 | -2,152,030 | -13,357,149.44 | -14,677,989.75 | -10,382,093.83 |
| 资产处置收益 | -1,771,123.17 | -10,730.91 | -1,030,018.7 | -339,646.19 |
| 信用减值损失(新) | 5,073,974.72 | -8,800,936.94 | -7,893,822.59 | -2,432,445.47 |
| 其他收益 | 12,995,099.04 | 50,271,066.63 | 22,178,251.97 | 15,966,371.41 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 108,359,629.25 | 270,069,503.79 | 237,023,065.21 | 86,438,503.18 |
| 加:营业外收入 | - | 61,581,462.69 | 59,797,427.27 | 59,784,316.49 |
| 减:营业外支出 | 1,132,320.36 | 9,576,402.29 | 5,035,575.45 | 4,015,837.18 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 107,227,308.89 | 322,074,564.19 | 291,784,917.03 | 142,206,982.49 |
| 减:所得税费用 | 13,436,506.36 | -11,541,140 | -2,337,500.48 | 629,648.77 |
| 六、净利润 | 93,790,802.53 | 333,615,704.19 | 294,122,417.51 | 141,577,333.72 |
| 持续经营净利润 | 93,790,802.53 | 333,615,704.19 | 294,122,417.51 | 141,577,333.72 |
| 归属于母公司股东的净利润 | 98,140,741.56 | 348,032,472.42 | 304,692,911.78 | 148,306,337.19 |
| 少数股东损益 | -4,349,939.03 | -14,416,768.23 | -10,570,494.27 | -6,729,003.47 |
| (一)基本每股收益 | 0.23 | 0.83 | 0.73 | 0.36 |
| (二)稀释每股收益 | 0.23 | 0.83 | 0.73 | 0.35 |
| 八、其他综合收益 | 147,493,168.22 | 60,755,488.95 | 8,433,019.48 | 33,925,385.56 |
| 归属于母公司股东的其他综合收益 | 147,493,168.22 | 60,755,488.95 | 8,433,019.48 | 33,925,385.56 |
| 九、综合收益总额 | 241,283,970.75 | 394,371,193.14 | 302,555,436.99 | 175,502,719.28 |
| 归属于母公司股东的综合收益总额 | 245,633,909.78 | 408,787,961.37 | 313,125,931.26 | 182,231,722.75 |
| 归属于少数股东的综合收益总额 | -4,349,939.03 | -14,416,768.23 | -10,570,494.27 | -6,729,003.47 |
| 公告日期 | 2024-04-20 | 2024-04-20 | 2023-10-25 | 2023-08-26 |
| 审计意见(境内) | | 标准无保留意见 | | |